CD86 and neoplasm: A significantly elevated expression of checkpoint inhibitors was detected in Cluster two tumours, including PD-1, PD-L1, CTLA4, CD80/CD86 costimulatory molecules, and emerging targets like TIGIT and LAG3 (Figures 3A–C).